Mumbai, March 18 -- The launch is significant, given India's large diabetic population. Empamore, containing the globally recognized SGLT2 inhibitor "Empagliflozin", offers a cost-effective alternative to leading brands. The product range of Empamore includes Empagliflozin in various dosages, addressing the growing diabetes market in India.

Morepen manufactures Empagliflozin (API) in its USFDA-approved facilities and already has European Drug Master File (DMF). The market price of Empagliflozin tablets has historically been high, making it inaccessible for many. With Morepen's launch of Empamore at a fraction of the cost, the company aims to capture a significant share of the rapidly growing diabetes market in India.

Morepen Laboratorie...